Sri Lanka Pharmaceuticals & Healthcare Report Q1 2016 - New Market Study Published

Sales of medicines in Sri Lanka will see reasonable growth ahead. Commercial opportunities are curtailed by the Sri Lanka's under-developed healthcare system and preference for generic drugs. Multinational drugmaker investments, which could catalyse the sector's growth, will be impaired by the dominant position of state-linked firms and the depreciation of the Sri Lankan rupee.

Headline Expenditure Projections

Pharmaceuticals: LKR75.1bn (USD575mn) in 2014 to LKR82bn (USD771mn) in 2015. Forecasts remain flat compared with the previous quarter with a downgrade in US dollar terms.
Healthcare: LKR282.5bn (USD2.2bn) in 2014 to LKR424.0bn (USD2.9bn) in 2015. Forecasts are slightly up compared with the previous quarter with a downgrade in US dollar terms.

Full Report Details at
- http://www.fastmr.com/prod/1109900_sri_lanka_pharmaceuticals.aspx?afid=301

Risk/Reward Index

Sri Lanka's Pharmaceutical Risk/Reward Index score for Q116 stands at 38.2 out of a total of 100, making it the seventeenth-most attractive pharmaceutical market out of 19 monitored in the Asia Pacific region. The main reason for the country's low score is the relatively small population size, which presents modest opportunities.

The Sri Lanka Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Sri Lanka Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Sri Lanka pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Sri Lanka, to test other views - a key input for successful budgeting and strategic business planning in the Sri Lankan pharmaceutical and healthcare market.
* Target business opportunities and risks in the Sri Lankan pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Sri Lanka.
* Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario



About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Sri Lanka Pharmaceuticals & Healthcare Report Q4 2015
- France Pharmaceuticals & Healthcare Report Q1 2016
- Saudi Arabia Pharmaceuticals & Healthcare Report Q1 2016
- Ukraine Pharmaceuticals & Healthcare Report Q1 2016
- Kenya Pharmaceuticals & Healthcare Report Q1 2016